24 Oct 2019 09:43
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (596/2014/EU) ("MAR"). WITH THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
October 24, 2019
Verseon Corporation
("Verseon" or the "Company")
Update on Sale-Leaseback of Verseon's Research, Development, and Operations Facility
FREMONT, Calif.-Further to the announcement of October 23, 2019, Verseon Corporation (AIM: VERS), a clinical-stage pharmaceutical company, today announces that it will not be in a position to sign the sale-leaseback for its research, development, and operations facility in Fremont, CA, (the "Facility") disclosed in yesterday's announcement ahead of the Annual General Meeting of Shareholders convened for October 28, 2019 ("AGM").
In order to enable the directors of the Company to enter into a sale-leaseback of the Facility and to consider options available to the Company, the resolution relating to the sale-leaseback will remain on the agenda for the AGM. The vote will proceed on the basis that the terms of the final sale-leaseback agreement will be materially similar or better than those announced on October 23, 2019.
- Ends -
For further information, please contact
Verseon Corporation | www.verseon.com |
Sebastian Wykeham / Tina Schlafly | +1 (510) 225 9000 |
Arden Partners (NOMAD and Broker) | |
Ruari McGirr / Ciaran Walsh / Dan Gee-Summons (Corporate Finance) / Fraser Marshall (Equity Sales) | +44 (0) 20 7614 5900 |
For trade and pharma media enquiries, please contact
Vane Percy & Roberts | |
Simon Vane Percy | +44 (0) 1737 821 890 |